← Back to Clinical Trials
Recruiting NCT07550647

NCT07550647 Early Rehabilitation After Total Hip Arthroplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07550647
Status Recruiting
Phase
Sponsor Muğla Sıtkı Koçman University
Condition Total Hip Arthroplasty (THA)
Study Type INTERVENTIONAL
Enrollment 52 participants
Start Date 2026-04
Primary Completion 2027-07

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Early Postoperative PhysiotherapyNeuromuscular Electrical Stimulation (NMES)Telerehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 52 participants in total. It began in 2026-04 with a primary completion date of 2027-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the effects of an early postoperative rehabilitation program combined with neuromuscular electrical stimulation (NMES) and telerehabilitation on functional recovery in patients undergoing total hip arthroplasty (THA). In the early postoperative period, patients commonly experience muscle weakness, impaired gait, and functional limitations that may delay recovery. Early rehabilitation has been shown to improve functional outcomes, while NMES may enhance muscle activation, particularly in hip abductor muscles. Additionally, telerehabilitation may support continuity of care following discharge by enabling supervised home-based exercise. In this prospective study, participants will be assigned to either an intervention group receiving early physiotherapy combined with NMES and telerehabilitation, or a control group receiving standard postoperative care. Functional outcomes, gait parameters, quality of life, and muscle-related changes will be evaluated at predefined time points.

Eligibility Criteria

Inclusion Criteria: * Patients scheduled for unilateral total hip arthroplasty due to osteoarthritis or developmental dysplasia of the hip (DDH) * Aged between 50 and 75 years * Willing and able to participate in all follow-up assessments * Able to comply with assessment procedures * Able to meet the requirements of telerehabilitation * Undergoing surgery with a standardized surgical protocol Exclusion Criteria: * Previous history of total hip arthroplasty on either side * Planned revision total hip arthroplasty * Severe osteoarthritis in the contralateral hip * Presence of severe acute metabolic, neuromuscular, or cardiovascular disease * History of active malignancy * Presence of respiratory infection * Concomitant orthopedic conditions (e.g., lower extremity fractures, severe hip/knee deformities, lumbar or sacroiliac dysfunction) * Body mass index \>35 * Occurrence of postoperative complications (e.g., prosthetic infection, thromboembolic events, or conditions requiring reoperation)

Contact & Investigator

Central Contact

Cansu Dal, Specialist Physiotherapist

✉ ptcansudal@gmail.com

📞 +905379773071

Frequently Asked Questions

Who can join the NCT07550647 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Total Hip Arthroplasty (THA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07550647 currently recruiting?

Yes, NCT07550647 is actively recruiting participants. Contact the research team at ptcansudal@gmail.com for enrollment information.

Where is the NCT07550647 trial being conducted?

This trial is being conducted at Niğde, Turkey (Türkiye).

Who is sponsoring the NCT07550647 clinical trial?

NCT07550647 is sponsored by Muğla Sıtkı Koçman University. The trial plans to enroll 52 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology